Medullary thyroid cancer: Molecular biology and novel molecular therapies

Neuroendocrinology

Volumn 90, Issue 4, 2009, Pages 323-348

  Cakir, Mehtap ^a,b   Grossman, Ashley B ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b SELCUK UNIVERSITY   (Turkey)

Author keywords

Medullary thyroid cancer; Molecular therapy; Pathogenesis

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; AXITINIB; BORTEZOMIB; CEP 751; GEFITINIB; IMATINIB; INDOMETACIN; IRINOTECAN; LESTAURTINIB; LITHIUM CHLORIDE; MOTESANIB; OCTREOTIDE; PAZOPANIB; PROTEIN RET; RC 3095; SEMAXANIB; SORAFENIB; SUCCINATE DEHYDROGENASE; SUNITINIB; TANESPIMYCIN; THALIDOMIDE; UNINDEXED DRUG; VALPROIC ACID; VANDETANIB; VORINOSTAT; XL 184;

ADVANCED CANCER; ALOPECIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CARCINOGENESIS; CELL CYCLE ARREST; CLINICAL TRIAL; CONSTIPATION; DENDRITIC CELL; DIARRHEA; DIZZINESS; DNA REPAIR; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FAMILIAL CANCER; FATIGUE; GAIN OF FUNCTION MUTATION; GASTRITIS; GENE LOSS; GENE MUTATION; GENE STRUCTURE; GENETIC POLYMORPHISM; HAND FOOT SYNDROME; HAPLOTYPE; HETEROZYGOSITY LOSS; HUMAN; HYPERTENSION; IC 50; INFECTION; INOPERABLE CANCER; LOSS OF FUNCTION MUTATION; LYMPH NODE METASTASIS; MEDLINE; METASTASIS; MOLECULAR BIOLOGY; MOLECULAR THERAPY; MONOTHERAPY; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROFIBROMATOSIS; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; POINT MUTATION; PRIORITY JOURNAL; PROTEINURIA; PROTO ONCOGENE; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SIPPLE SYNDROME; SKIN TOXICITY; SOLID TUMOR; SOMATIC MUTATION; SOMNOLENCE; STOMACH HEMORRHAGE; STOMACH ULCER; STOMATITIS; THROMBOCYTOPENIA; THYROID CANCER; THYROID DISEASE; THYROID MEDULLARY CARCINOMA; TRACHEOESOPHAGEAL FISTULA; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; PROTO-ONCOGENE PROTEINS C-RET; SIGNAL TRANSDUCTION; SUCCINATE DEHYDROGENASE; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 71849111319     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000220827     Document Type: Review

References (177)

1. Hazard JB, Hawk WA, Crile G Jr: Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab 1959; 19: 152-161.
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR: A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 1998; 83: 2638-2648.
3. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB: RET proto-oncogene: A review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005; 15: 531-544.
4. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Mulligan LM, et al: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996; 276: 1575-1579.
5. Eng C: RET proto-oncogene in the development of human cancer. J Clin Oncol 1999; 17: 380-393.
6. Phay JE, Moley JF, Lairmore TC: Multiple endocrine neoplasias. Semin Surg Oncol 2000; 18: 324-332.
7. Lodish MB, Stratakis CA: RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Rev Anticancer Ther 2008; 8: 625-632.
8. Block MA, Jackson CE, Greenawald KA, Yott JB, Tashjian AH Jr: Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Treatment implications. Arch Surg 1980; 115: 142-148.
9. Hoff AO, Hoff PM: Medullary thyroid carcinoma. Hematol Oncol Clin North Am 2007; 21: 475-488.
10. Lemos MC, Carrilho F, Rodrigues FJ, Santos P, Carvalheiro M, Ruas MA, Regateiro FJ: Early onset of medullary thyroid carcinoma in a kindred with multiple endocrine neoplasia type IIA associated with cutaneous lichen amyloidosis. Endocr Pract 2002; 8: 19-22.
11. Kaufman FR, Roe TF, Isaacs H Jr, Weitzman JJ: Metastatic medullary thyroid carcinoma in young children with mucosal neuroma syndrome. Pediatrics 1982; 70: 263-267.
12. Tsui-Pierchala BA, Ahrens RC, Crowder RJ, Milbrandt J, Johnson EM Jr: The long and short isoforms of Ret function as independent signaling complexes. J Biol Chem 2002; 277: 34618-34625.
13. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB: Multiple endocrine neoplasia type 2: Evaluation of the genotype-phenotype relationship. Arch Surg 2003; 138: 409-416.
14. Machens A, Dralle H: Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg 2007; 31: 957-968.
15. Leboulleux S, Baudin E, Travagli JP, Schlumberger M: Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004; 61: 299-310.
16. Pasini B, Hofstra RM, Yin L, Bocciardi R, Santamaria G, Grootscholten PM, Ceccherini I, Patrone G, Priolo M, Buys CH, et al: The physical map of the human RET proto-oncogene. Oncogene 1995; 11: 1737-1743.
17. de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM: RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006; 27: 535-560.
18. Airaksinen MS, Saarma M: The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002; 3: 383-394.
19. de Graaff E, Srinivas S, Kilkenny C, D'Agati V, Mankoo BS, Costantini F, Pachnis V: Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis. Genes Dev 2001; 15: 2433-2444.
20. Lee DC, Chan KW, Chan SY: RET receptor tyrosine kinase isoforms in kidney function and disease. Oncogene 2002; 21: 5582-5592.
21. Castellone MD, Santoro M: Dysregulated RET signaling in thyroid cancer. Endocrinol Metab Clin North Am 2008; 37: 363-374.
22. Segouffin-Cariou C, Billaud M: Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/ AKT signaling pathway. J Biol Chem 2000; 275: 3568-3576.
23. Jijiwa M, Fukuda T, Kawai K, Nakamura A, Kurokawa K, Murakumo Y, Ichihara M, Takahashi M: A targeting mutation of tyrosine 1062 in Ret causes a marked decrease of enteric neurons and renal hypoplasia. Mol Cell Biol 2004; 24: 8026-8036.
24. Scott RP, Eketjall S, Aineskog H, Ibanez CF: Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase. J Biol Chem 2005; 280: 13442-13449.
25. Reynolds L, Jones K, Winton DJ, Cranston A, Houghton C, Howard L, Ponder BA, Smith DP: C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET. Oncogene 2001; 20: 3986-13894
26. Acton DS, Velthuyzen D, Lips CJ, Hoppener JW: Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice. Oncogene 2000; 19: 3121-3125.
27. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, et al: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458-460.
28. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2: 851-856.
29. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA Jr, Goodfellow PJ, Donis-Keller H: Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 1994; 91: 1579-1583.
30. Boikos SA, Stratakis CA: Molecular mechanisms of medullary thyroid carcinoma: current approaches in diagnosis and treatment. Histol Histopathol 2008; 23: 109-116.
31. Diaz-Cano SJ, de Miguel M, Blanes A, Tashjian R, Wolfe HJ: Germline RET 634 mutation positive MEN 2A-related C-cell hyperplasias have genetic features consistent with intraepithelial neoplasia. J Clin Endocrinol Metab 2001; 86: 3948-3957.
32. Elisei R, Cosci B, Romei C, Agate L, Piampiani P, Miccoli P, Berti P, Basolo F, Ugolini C, Ciampi R, Nikiforov Y, Pinchera A: Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. J Clin Endocrinol Metab 2004; 89: 5823-5827.
33. Lesueur F, Cebrian A, Cranston A, Leyland J, Faid TM, Clements MR, Robledo M, Whittaker J, Ponder BA: Germline homozygous mutations at codon 804 in the RET protooncogene in medullary thyroid carcinoma/ multiple endocrine neoplasia type 2A patients. J Clin Endocrinol Metab 2005; 90: 3454-3457.
34. Huang SC, Torres-Cruz J, Pack SD, Koch CA, Vortmeyer AO, Mannan P, Lubensky IA, Gagel RF, Zhuang Z: Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 459-463.
35. Koch CA, Huang SC, Moley JF, Azumi N, Chrousos GP, Gagel RF, Zhuang Z, Pacak K, Vortmeyer AO: Allelic imbalance of the mutant and wild-type RET allele in MEN 2Aassociated medullary thyroid carcinoma. Oncogene 2001; 20: 7809-17011
36. Kjaer S, Kurokawa K, Perrinjaquet M, Abrescia C, Ibanez CF: Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations. Oncogene 2006; 25: 7086-7095.
37. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, et al: Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995; 267: 381-383.
38. Runeberg-Roos P, Virtanen H, Saarma M: RET(MEN 2B) is active in the endoplasmic reticulum before reaching the cell surface. Oncogene 2007; 26: 7909-7915.
39. Carlomagno F, Melillo RM, Visconti R, Salvatore G, De Vita G, Lupoli G, Yu Y, Jing S, Vecchio G, Fusco A, Santoro M: Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease. Endocrinology 1998; 139: 3613-3619.
40. Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G, Takahashi M: Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. Cancer Res 1997; 57: 2870-2872.
41. Carlomagno F, Salvatore G, Cirafici AM, De Vita G, Melillo RM, de Franciscis V, Billaud M, Fusco A, Santoro M: The different RETactivating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res 1997; 57: 391-395.
42. Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Novak Z, Duskova J, Ryska A, Laco J, Cap J, Kodetova D, Kodet R, Krskova L, Vlcek P, Astl J, Vesely D, Bendlova B: Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 2008; 284: 21-27.
43. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A: Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10-year followup study. J Clin Endocrinol Metab 2008; 93: 682-687.
44. Erdogan MF, Gursoy A, Ozgen G, Cakir M, Bayram F, Ersoy R, Algun E, Cetinarslan B, Comlekci A, Kadioglu P, Balci MK, Yetkin I, Kabalak T, Erdogan G: Ret proto-oncogene mutations in apparently sporadic Turkish medullary thyroid carcinoma patients: Turkmen study. J Endocrinol Invest 2005; 28: 806-809.
45. Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L, Pacini F, Pinchera A: RET genetic screening in patients with medullary thyroid cancer and their relatives: Experience with 807 individuals at one center. J Clin Endocrinol Metab 2007; 92: 4725-4729.
46. Eng C, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Thomas GA, Ponder BA: Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 1996; 56: 2167-2170. (Pubitemid 26119920)
47. Schilling T, Burck J, Sinn HP, Clemens A, Otto HF, Hoppner W, Herfarth C, Ziegler R, Schwab M, Raue F: Prognostic value of codon 918 (ATG ] ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 2001; 95: 62-66.
48. Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallengren B, Grimelius L, Backdahl M, Weber G, Wallin G: Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 1995; 80: 3088-3090.
49. Frisk T, Zedenius J, Lundberg J, Wallin G, Kytola S, Larsson C: CGH alterations in medullary thyroid carcinomas in relation to the RET M918T mutation and clinical outcome. Int J Oncol 2001; 18: 1219-1225.
50. Marsh DJ, Theodosopoulos G, Martin- Schulte K, Richardson AL, Philips J, Roher HD, Delbridge L, Robinson BG: Genomewide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 1866-1872.
51. Salvatore D, Melillo RM, Monaco C, Visconti R, Fenzi G, Vecchio G, Fusco A, Santoro M: Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. Cancer Res 2001; 61: 1426-1431.
52. Bocciardi R, Mograbi B, Pasini B, Borrello MG, Pierotti MA, Bourget I, Fischer S, Romeo G, Rossi B: The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Oncogene 1997; 15: 2257-2265.
53. Murakami H, Yamamura Y, Shimono Y, Kawai K, Kurokawa K, Takahashi M: Role of Dok1 in cell signaling mediated by RET tyrosine kinase. J Biol Chem 2002; 277: 32781-32790.
54. Marshall GM, Peaston AE, Hocker JE, Smith SA, Hansford LM, Tobias V, Norris MD, Haber M, Smith DP, Lorenzo MJ, Ponder BA, Hancock JF: Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase. Cancer Res 1997; 57: 5399-5405.
55. Hasegawa T, Enomoto A, Kato T, Kawai K, Miyamoto R, Jijiwa M, Ichihara M, Ishida M, Asai N, Murakumo Y, Ohara K, Niwa Y, Goto H, Takahashi M: Roles of induced expression of MAPK phosphatase-2 in tumour development in RET-MEN2A transgenic mice. Oncogene 2008 Jun 9. [Epub ahead of print].
56. Vaccaro A, Chen H, Kunnimalaiyaan M: Invivo activation of Raf-1 inhibits tumour growth and development in a xenograft model of human medullary thyroid cancer. Anticancer Drugs 2006; 17: 849-853.
57. Plaza-Menacho I, van der Sluis T, Hollema H, Gimm O, Buys CH, Magee AI, Isacke CM, Hofstra RM, Eggen BJ: Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation. J Biol Chem 2007; 282: 6415-6424.
58. Plaza-Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, Hollema H, Burzynski GM, Gimm O, Buys CH, Eggen BJ, Hofstra RM: RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res 2005; 65: 1729-1737.
59. Lin H, Chen MC, Chiu CY, Song YM, Lin SY: Cdk5 regulates STAT3 activation and cell proliferation in MTC cells. J Biol Chem 2007; 282: 2776-2784.
60. Gujral TS, van Veelen W, Richardson DS, Myers SM, Meens JA, Acton DS, Dunach M, Elliott BE, Hoppener JW, Mulligan LM: A novel RET kinase-beta-catenin signaling pathway contributes to tumourigenesis in thyroid carcinoma. Cancer Res 2008; 68: 1338-1346.
61. Gallel P, Pallares J, Dolcet X, Llobet D, Eritja N, Santacana M, Yeramian A, Palomar- Asenjo V, Lagarda H, Mauricio D, Encinas M, Matias-Guiu X: Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma. Hum Pathol 2008; 39: 994-1001.
62. Montani M, Schmitt AM, Schmid S, Locher T, Saremaslani P, Heitz PU, Komminoth P, Perren A: No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma. Endocr Relat Cancer 2005; 12: 1011-1016.
63. Sobrinho-Simoes M, Maximo V, Rocha AS, Trovisco V, Castro P, Preto A, Lima J, Soares P: Intragenic mutations in thyroid cancer. Endocrinol Metab Clin North Am 2008; 37: 333-362.
64. Cascon A, Cebrian A, Pollan M, Ruiz-Llorente S, Montero-Conde C, Leton R, Gutierrez R, Lesueur F, Milne RL, Gonzalez-Albarran O, Lucas-Morante T, Benitez J, Ponder BA, Robledo M: Succinate dehydrogenase D variants do not constitute a risk factor for developing C cell hyperplasia or sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 2005; 90: 2127-2130.
65. Ceccherini I, Hofstra RM, Luo Y, Stulp RP, Barone V, Stelwagen T, Bocciardi R, Nijveen H, Bolino A, Seri M, et al: DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene. Oncogene 1994; 9: 3025-3029.
66. Robledo M, Gil L, Pollan M, Cebrian A, Ruiz S, Azanedo M, Benitez J, Menarguez J, Rojas JM: Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Res 2003; 63: 1814-1817.
67. Lesueur F, Cebrian A, Robledo M, Niccoli- Sire P, Svensson KA, Pinson S, Leyland J, Whittaker J, Pharoah PD, Ponder BA: Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A. Cancer Res 2006; 66: 1177-1180.
68. Fernandez RM, Navarro E, Antinolo G, Ruiz-Ferrer M, Borrego S: Evaluation of the role of RET polymorphisms/haplotypes as modifier loci for MEN 2, and analysis of the correlation with the type of RET mutation in a series of Spanish patients. Int J Mol Med 2006; 17: 575-581.
69. Baumgartner-Parzer SM, Lang R, Wagner L, Heinze G, Niederle B, Kaserer K, Waldhausl W, Vierhapper H: Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? J Clin Endocrinol Metab 2005; 90: 6232-6236.
70. Gimm O, Neuberg DS, Marsh DJ, Dahia PL, Hoang-Vu C, Raue F, Hinze R, Dralle H, Eng C: Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene 1999; 18: 1369-1373.
71. Berard I, Kraimps JL, Savagner F, Murat A, Renaudin K, Nicolli-Sire P, Bertrand G, Moisan JP, Bezieau S: Germline-sequence variants S836S and L769L in the RE arranged during Transfection (RET) proto-oncogene are not associated with predisposition to sporadic medullary carcinoma in the French population. Clin Genet 2004; 65: 150-152.
72. Elisei R, Cosci B, Romei C, Bottici V, Sculli M, Lari R, Barale R, Pacini F, Pinchera A: RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab 2004; 89: 3579-3584.
73. Wiench M, Woch J, Wygoda Z, Gubaa E, Oczko M, Pawlaczek A, Kula D, Lange D, Jarzab B: RET polymorphisms in codons 769 and 836 are not associated with predisposition to medullary thyroid carcinoma. Cancer Detect Prev 2004; 28: 231-236.
74. Wohllk GN, Soto CE, Bravo AM, Becker CP: G691S, L769L and S836S ret proto-oncogene polymorphisms are not associated with higher risk to sporadic medullary thyroid carcinoma in Chilean patients (in Spanish). Rev Med Chil 2005; 133: 397-402.
75. Costa P, Domingues R, Sobrinho LG, Bugalho MJ: RET polymorphisms and sporadic medullary thyroid carcinoma in a Portuguese population. Endocrine 2005; 27: 239-243.
76. Gursoy A, Erdogan MF, Erdogan G: Significance of the RET proto-oncogene polymorphisms in Turkish sporadic medullary thyroid carcinoma patients. J Endocrinol Invest 2006; 29: 858-862.
77. Cebrian A, Lesueur F, Martin S, Leyland J, Ahmed S, Luccarini C, Smith PL, Luben R, Whittaker J, Pharoah PD, Dunning AM, Ponder BA: Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 2005; 90: 6268-6274.
78. Ruiz A, Antinolo G, Fernandez RM, Eng C, Marcos I, Borrego S: Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population. Clin Endocrinol (Oxf) 2001; 55: 399-402.
79. Borrego S, Wright FA, Fernandez RM, Williams N, Lopez-Alonso M, Davuluri R, Antinolo G, Eng C: A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma. Am J Hum Genet 2003; 72: 88-100.
80. Fernandez RM, Pecina A, Antinolo G, Navarro E, Borrego S: Analysis of RET polymorphisms and haplotypes in the context of sporadic medullary thyroid carcinoma. Thyroid 2006; 16: 411-417.
81. Fitze G, Schierz M, Kuhlisch E, Schreiber M, Ziegler A, Roesner D, Schackert HK: Novel intronic polymorphisms in the RET protooncogene and their association with Hirschsprung disease. Hum Mutat 2003; 22: 177.
82. Gimm O, Dziema H, Brown J, Hoang-Vu C, Hinze R, Dralle H, Mulligan LM, Eng C: Over-representation of a germline variant in the gene encoding RET co-receptor GFR - -1 but not GFR - -2 or GFR - -3 in cases with sporadic medullary thyroid carcinoma. Oncogene 2001; 20: 2161-2170.
83. Borrego S, Fernandez RM, Dziema H, Japon MA, Marcos I, Eng C, Antinolo G: Evaluation of germline sequence variants of GFRA1, GFRA2, and GFRA3 genes in a cohort of Spanish patients with sporadic medullary thyroid cancer. Thyroid 2002; 12: 1017-1022.
84. Ruiz-Llorente S, Montero-Conde C, Milne RL, Moya CM, Cebrian A, Leton R, Cascon A, Mercadillo F, Landa I, Borrego S, Perez de Nanclares G, Alvarez-Escola C, Diaz-Perez JA, Carracedo A, Urioste M, Gonzalez-Neira A, Benitez J, Santisteban P, Dopazo J, Ponder BA, Robledo M; Medullary Thyroid Carcinoma Clinical Group: Association study of 69 genes in the ret pathway identifies lowpenetrance loci in sporadic medullary thyroid carcinoma. Cancer Res 2007; 67: 9561-9567.
85. Fugazzola L, Muzza M, Mian C, Cordella D, Barollo S, Alberti L, Cirello V, Dazzi D, Girelli ME, Opocher G, Beck-Peccoz P, Persani L: RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series. Clin Endocrinol (Oxf) 2008 Feb 11. [Epub ahead of print] .
86. Goutas N, Vlachodimitropoulos D, Bouka M, Lazaris AC, Nasioulas G, Gazouli M: BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res 2008; 28: 305-308.
87. van Veelen W, van Gasteren CJ, Acton DS, Franklin DS, Berger R, Lips CJ, Hoppener JW: Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development. Cancer Res 2008; 68: 1329-1337.
88. Franklin DS, Godfrey VL, O'Brien DA, Deng C, Xiong Y: Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumour growth with distinct tissue specificity. Mol Cell Biol 2000; 20: 6147-6158.
89. Joshi PP, Kulkarni MV, Yu BK, Smith KR, Norton DL, Veelen W, Hoppener JW, Franklin DS: Simultaneous downregulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2A-RET-mediated mitogenesis. Oncogene 2007; 26: 554-570.
90. Pavelic K, Dedivitis RA, Kapitanović S, Cacev T, Guirado CR, Danić D, Radosević S, Brkić K, Pegan B, Krizanac S, Kusić Z, Spaventi S, Bura M: Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions. Mutation Res 2006; 599: 45-57.
91. Cho MA, Lee MK, Nam KH, Chung WY, Park CS, Lee JH, Noh T, Yang WI, Rhee Y, Lim SK, Lee HC, Lee EJ: Expression and role of estrogen receptor alpha and beta in medullary thyroid carcinoma: Different roles in cancer growth and apoptosis. J Endocrinol 2007; 195: 255-263.
92. Egawa C, Miyoshi Y, Iwao K, Shiba E, Noguchi S: Quantitative analysis of estrogen receptor- alpha and -beta messenger RNA expression in normal and malignant thyroid tissues by real-time polymerase chain reaction. Oncology 2001; 61: 293-298. (Pubitemid 33135838)
93. Blechet C, Lecomte P, De Calan L, Beutter P, Guyetant S: Expression of sex steroid hormone receptors in C cell hyperplasia and medullary thyroid carcinoma. Virchows Arch 2007; 450: 433-439.
94. Stadler G, Wieser M, Streubel B, Stift A, Friedl J, Gnant M, Niederle B, Beham A, Katinger H, Pfragner R, Grillari J, Voglauer R: Low telomerase activity: Possible role in the progression of human medullary thyroid carcinoma. Eur J Cancer 2008; 44: 866-875.
95. Popovtzer A, Morgenstein S, Roizman P, Gutman D, Bahar G, Stern Y, Feinmesser R: Cyclooxygenase-2 expression in medullary thyroid carcinoma. Head Neck 2007; 29: 559-563.
96. Santarpia L , Ye L, Cote GJ, El-Naggar AK, Gagel RF: High resolution CGH profiling of medullary thyroid carcinoma tumours reveals a predominance of genetic loss. (P2- 247) Presented at the 90th Annual Meeting of the Endocrine Society (ENDO 08): 2008 June 15-18, San Francisco, Calif.
97. Ye L, Santarpia L , Cote GJ, El-Naggar AK, Gagel RF: Allelic loss of DNA repair pathway genes occurs in medullary thyroid carcinoma. (OR54-1) Presented at the 90th Annual Meeting of the Endocrine Society (ENDO 08): 2008 June 15-18, San Francisco, Calif.
98. Abu-Amero KK, Alzahrani AS, Zou M, Shi Y: Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome. Oncogene 2006; 25: 677-684.
99. Zatelli MC, Tagliati F, Amodio V, Rossi R, Trasforini G, Frigato G, Bondanelli M, degli Uberti E: Possible oncogenic role for pituitary transforming gene-1 (PTTG-1) in medullary thyroid carcinoma. Thyroid 2008; 18(suppl 1):S1-S5.
100. Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N: Antitumour effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 2006; 91: 4013-4021.
101. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H: Inactivation of glycogen synthase kinase-3 - , a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther 2007; 6: 1151-1158.
102. Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G, Goudopoulou A, Richon VM, Marks PA, Mitsiades N: Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res 2005; 11: 3958-3965.
103. Ning L, Jaskula-Sztul R, Kunnimalaiyaan M, Chen H: Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumour progression in an animal model of medullary thyroid carcinoma. Ann Surg Oncol 2008; 15: 2600-2605.
104. Greenblatt DY, Cayo MA, Adler JT, Ning L, Haymart MR, Kunnimalaiyaan M, Chen H: Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells. Ann Surg 2008; 247: 1036-1040. (Pubitemid 351770425)
105. Strock CJ, Park JI, Rosen DM, Ruggeri B, Denmeade SR, Ball DW, Nelkin BD: Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab 2006; 91: 79-84.
106. Strock CJ, Park JI, Rosen M, Dionne C, Ruggeri B, Jones-Bolin S, Denmeade SR, Ball DW, Nelkin BD: CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res 2003; 63: 5559-5563.
107. Tagliati F, Zatelli MC, Bottoni A, Piccin D, Luchin A, Culler MD, degli Uberti EC: Role of complex cyclin d1/cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro. Endocrinology 2006; 147: 3530-3538.
108. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A, Vignali C, Margutti A, Bondanelli M, Pansini GC, Pelizzo MR, Culler MD, degli Uberti EC: Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: Potential clinical perspectives. J Clin Endocrinol Metab 2006; 91: 2218-2224.
109. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A, degli Uberti EC: SRC homology- 2-containing protein tyrosine phosphatase- 1 restrains cell proliferation in human medullary thyroid carcinoma. Endocrinology 2005; 146: 2692-2698.
110. Zatelli MC, Luchin A, Piccin D, Tagliati F, Bottoni A, Vignali C, Bondanelli M, degli Uberti EC: Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J Clin Endocrinol Metab 2005; 90: 5754-5760.
111. Zatelli MC, Tagliati F, Taylor JE, Piccin D, Culler MD, degli Uberti EC: Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. Horm Metab Res 2002; 34: 229-233.
112. Zatelli MC, Tagliati F, Piccin D, Taylor JE, Culler MD, Bondanelli M, degli Uberti EC: Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 2002; 297: 828-834.
113. Quidville V, Segond N, Lausson S, Frenkian M, Cohen R, Jullienne A: 15-Hydroxyprostaglandin- dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line. Prostaglandins Other Lipid Mediat 2006; 81: 14-30.
114. Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, Stephan C, Grosios K, Wartmann M, Cozens R, Caravatti G, Fabbro D, Lane HA, Fagin JA: The RET kinase inhibitor NVPAST487 blocks growth and calcitonin geneexpression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res 2007; 67: 6956-6964.
115. Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, Seregni E, Martinetti A, Laccabue D, Zanchi C, Zunino F: Cellular effects and antitumour activity of RET inhibitor RPI-1 on MEN2Aassociated medullary thyroid carcinoma. J Natl Cancer Inst 2004; 96: 1006-1014.
116. Petrangolini G, Cuccuru G, Lanzi C, Tortoreto M, Belluco S, Pratesi G, Cassinelli G, Zunino F: Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1. Biochem Pharmacol 2006; 72: 405-414.
117. Kunnimalaiyaan M, Ndiaye M, Chen H: Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery 2006; 140: 1009-1014.
118. Ludwig L, Kessler H, Wagner M, Hoang-Vu C, Dralle H, Adler G, Bohm BO, Schmid RM: Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res 2001; 61: 4526-4535.
119. Ezzat S, Huang P, Dackiw A, Asa SL: Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res 2005; 11: 1336-1341.
120. Croyle M, Akeno N, Knauf JA, Fabbro D, Chen X, Baumgartner JE, Lane HA, Fagin JA: RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: Evidence for molecular and functional interactions between RET and EGFR. Cancer Res 2008; 68: 4183-4191.
121. Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, Gazit A, Levitzki A, Santoro M: The kinase inhibitor PP1 blocks tumourigenesis induced by RET oncogenes. Cancer Res 2002; 62: 1077-1082.
122. Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone MD, Melillo RM, Fusco A, Santoro M: Efficient inhibition of RET/ papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7- (t-butyl)pyrazolo[3,4-d] pyrimidine (PP2). J Clin Endocrinol Metab 2003; 88: 1897- 1902.
123. Morisi R, Celano M, Tosi E, Schenone S, Navarra M, Ferretti E, Costante G, Durante C, Botta G, D'Agostino M, Brullo C, Filetti S, Botta M, Russo D: Growth inhibition of medullary thyroid carcinoma cells by pyrazolo- pyrimidine derivates. J Endocrinol Invest 2007; 30:RC31-RC34.
124. Mologni L, Sala E, Cazzaniga S, Rostagno R, Kuoni T, Puttini M, Bain J, Cleris L, Redaelli S, Riva B, Formelli F, Scapozza L, Gambacorti-Passerini C: Inhibition of RET tyrosine kinase by SU5416. J Mol Endocrinol 2006; 37: 199-212.
125. Graham Robinett R, Freemerman AJ, Skinner MA, Shewchuk L, Lackey K: The discovery of substituted 4-(3-hydroxyanilino)- quinolines as potent RET kinase inhibitors. Bioorg Med Chem Lett 2007; 17: 5886-5893.
126. Dadan J, Woczyski S, Sawicki B, Chyczewski L, Azzadin A, Dziecio J, Puchalski Z: Preliminary evaluation of influence of gemcitabine (Gemzar) on proliferation and neuroendocrine activity of human TT cell line: Immunocytochemical investigations. Folia Histochem Cytobiol 2001; 39: 187-188.
127. Marsee DK, Venkateswaran A, Tao H, Vadysirisack D, Zhang Z, Vandre DD, Jhiang SM: Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells. J Biol Chem 2004; 279: 43990-43997.
128. Iervolino A, Iuliano R, Trapasso F, Viglietto G, Melillo RM, Carlomagno F, Santoro M, Fusco A: The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. Cancer Res 2006; 66: 6280-6287.
129. Qiao S, Iwashita T, Furukawa T, Yamamoto M, Sobue G, Takahashi M: Differential effects of leukocyte common antigen-related protein on biochemical and biological activities of RET-MEN2A and RET-MEN2B mutant proteins. J Biol Chem 2001; 276: 9460-9467.
130. Hennige AM, Lammers R, Hoppner W, Arlt D, Strack V, Teichmann R, Machicao F, Ullrich A, Haring HU, Kellerer M: Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1. Endocrinology 2001; 142: 4441-4447.
131. Cerchia L, Duconge F, Pestourie C, Boulay J, Aissouni Y, Gombert K, Tavitian B, de Franciscis V, Libri D: Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol 2005; 3:e123.
132. Du Zx, Zhang HY, Gao da X, Wang HQ, Li YJ, Liu GL: Anti-survivin oligonucleotides were reported to inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells. Exp Mol Med 2006; 38: 230-240.
133. Mustafa T, Rothe U, Dolling K, Klonisch T, Chen Z, Zahl C, Gerlach KL, Dralle H, Hoang-Vu C: Effect of betulinic acid and its derivatative, betulinic acid butyrate ester (BABE), on the CD97 expression in medullary thyroid carcinoma cell lines. Thyroid 2008; 18(s1):S20.
134. Cerchia L, Libri D, Carlomagno MS, de Franciscis V: The soluble ectodomain of RetC634Y inhibits both the wild-type and the constitutively active Ret. Biochem J 2003; 372: 897-903.
135. Yano L, Shimura M, Taniguchi M, Hayashi Y, Suzuki T, Hatake K, Takaku F, Ishizaka Y: Improved gene transfer to neuroblastoma cells by a monoclonal antibody targeting RET, a receptor tyrosine kinase. Hum Gene Ther 2000; 11: 995-1004.
136. Salvatore G, Nagata S, Billaud M, Santoro M, Vecchio G, Pastan I: Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase. Biochem Biophys Res Commun 2002; 294: 813-817.
137. Stein R, Goldenberg DM: A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumour growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther 2004; 3: 1559-1564.
138. Schott M: Immunesurveillance by dendritic cells: Potential implication for immunotherapy of endocrine cancers. Endocr Relat Cancer 2006; 13: 779-795. (Pubitemid 44763257)
139. Messina M, Robinson BG: Technology insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 2007; 3: 290-301.
140. Matuszczyk A, Petersenn S, Bockisch A, Gorges R, Sheu SY, Veit P, Mann K: Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2008; 40: 210-213.
141. Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M: Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FUdacarbazine. Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 2000; 83: 715-718.
142. Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP 3rd: Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 1994; 73: 432-436.
143. Cooney MM, Ortiz J, Bukowski RM, Remick SC: Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds. Curr Oncol Rep 2005; 7: 90-95.
144. Nelkin BD, Ball DW: Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 2001; 8: 157-160.
145. Kaczirek K, Schindl M, Weinhausel A, Scheuba C, Passler C, Prager G, Raderer M, Hamilton G, Mittlbock M, Siegl V, Pfragner R, Niederle B: Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines. J Clin Endocrinol Metab 2004; 89: 2397-2401.
146. Izquierdo MA, Bowman A, Garcia M, Jodrell D, Martinez M, Pardo B, Gomez J, Lopez-Martin JA, Jimeno J, Germa JR,Smyth JF: Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumours. Clin Cancer Res 2008; 14: 3105-3112.
147. Labidi SI, Gravis G, Tarpin C, Brun V, Viens P: Medullary thyroid cancer treated by capecitabine. Anticancer Drugs 2007; 18: 831-834.
148. Paiva CE, Michelin OC: Use of capecitabine in refractory, metastatic medullary thyroid carcinoma. Thyroid 2008; 18: 587.
149. Faivre S, Chieze S, Delbaldo C, Ady-Vago N, Guzman C, Lopez-Lazaro L, Lozahic S, Jimeno J, Pico F, Armand JP, Martin JA, Raymond E: Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol 2005; 23: 7871-7880.
150. Ball DW: Medullary thyroid cancer: Therapeutic targets and molecular markers. Curr Opin Oncol 2007; 19: 18-23.
151. Koch CA, Brouwers FM, Vortmeyer AO, Tannapfel A, Libutti SK, Zhuang Z, Pacak K, Neumann HP, Paschke R: Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer 2006; 6: 131.
152. Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ: Vandetanib (ZD6474): An orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumour growth and angiogenesis. Expert Opin Investig Drugs 2007; 16: 239-249.
153. Wells SA, Gosnell JE, Gagel RF, Moley JF, Pfister DG, Sosa JA, Skinner M, Krebs A, Hou J, Schlumberger M: Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. 2007 ASCO Annual Meeting Proceedings Part I (abstract 6018). J Clin Oncol 2007; 25(18S).
154. Haddad RI, Krebs AD, Vasselli J, Paz-Ares LG, Robinson B: A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer (abstract 6024). 2008 ASCO Annual Meeting. J Clin Oncol 2008; 26(suppl).
155. ClinicalTrials.gov. National Institutes of Health. Available at: Www.clinicaltrials.gov/ct2/home. Accessed 25 September 2008.
156. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S: Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-844.
157. Kober F, Hermann M, Handler A, Krotla G: Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. 2007 ASCO Annual Meeting Proceedings Part I (abstract 14065). J Clin Oncol 2007; 25(18S).
158. Ahmed M, Barbachano Y, Riddell AM, Whittaker S, Newbold K, Harrington K, Marais R, Nutting CM: Preliminary results of an open labelled phase 2 study evaluating the safety and efficacy of sorafenib in metastatic advanced thyroid cancer (abstract 6060). 2008 ASCO Annual Meeting J Clin Oncol 2008; 26(suppl).
159. Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, Kurzrock R: Medullary thyroid cancer: Targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 2008; 7: 1001-1006.
160. Chintala L, Kurzrock R, Fu S, Naing A, Wheler JJ, Moulder SL, Newman R, Gagel R, Sebti S, Wright JJ, Hong DS: Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancer (NCI protocol 7156, abstract 3593). 2008 ASCO Annual Meeting J Clin Oncol 2008; 26 (suppl).
161. Sebolt-Leopold JS, English JM: Mechanisms of drug inhibition of signalling molecules. Nature 2006; 441: 457-462.
162. Sherman SI: Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am 2008; 37: 511-524, xi.
163. Kelleher FC, McDermott R: Response to sunitinib in medullary thyroid cancer. Ann Intern Med 2008; 148: 567.
164. Cohen EE, Needles BM, Cullen KJ, Wong SJ, Wade JL, Ivy SP, Villaflor VM, Seiwert TY, Nichols K, Vokes EE: Phase 2 study of sunitinib in refractory thyroid cancer (abstract 6025). 2008 ASCO Annual Meeting J Clin Oncol 2008; 26(suppl).
165. Cohen EE, Vokes EE, Rosen LS, Kies MS, Forastiere AA, Worden FP, Kane MA, Liau KF, Shalinsky DR, Cohen RB: A phase II study of axitinib (AG-013736[AG]) in patients with advanced thyroid cancers. 2007 ASCO Annual Meeting Proceedings Part I (abstract 6008). J Clin Oncol 2007; 25(18S).
166. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, Voest EE: A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 3466-3469.
167. Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A, Slavin S; The Israel Glivec in Solid Tumors Study Group: The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumours positive for c-kit or PDGF-R. Endocr Related Cancer 2006; 13: 535-540.
168. Frank-Raue K, Fabel M, Delorme S, Haberkorn U, Raue F: Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 2007; 157: 215-220.
169. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ: Phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008; 18: 317-323.
170. Schlumberger M, Elisei R, Sherman SI, Bastholt L, Wirth L, Martins RG, Licitra L, Jarzab B, Pacini F, Daumerie C, Droz JP, Shi Y, Sun Y, Stepan DE: Phase 2 trial of motesanib diphosphate (AMG 706) in patients with medullary thyroid cancer (MTC). (OR39-3). 89th Annual Meeting of the Endocrine Society (ENDO 07): June 2-5, 2007, Toronto, Ont.
171. Salgia R, Sherman S, Hong DS, Ng CS, Frye J, Janisch L, Ratain MJ, Kurzrock R: A phase I study of XL 184, a RET, VEGFR2, and MET kinase inhibitor, in patients with advanced malignancies, including patients with medullary thyroid cancer (MTC) (abstract 3522). 2008 ASCO Annual Meeting J Clin Oncol 2008; 26(suppl).
172. Kurzrock R, Sherman S, Hong D, Ng C, Frye J, Janisch L, Ratain MJ, Salgia R: Preliminary results of a phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor administered orally to patients with medullary thyroid cancer. Thyroid 2008; 18: S34-S35.
173. Ain KB, Lee C, Williams KD: Phase II trial of thalidomide for therapy of radioiodineunresponsive and rapidly progressive thyroid carcinomas. Thyroid 2007; 17: 663-670.
174. Schwartsmann G, DiLeone LP, Horowitz M, Schunemann D, Cancella A, Pereira AS, Richter M, Souza F, da Rocha AB, Souza FH, Pohlmann P, De Nucci G: A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest New Drugs 2006; 24: 403-412.
175. Diez JJ, Iglesias P: Somatostatin analogs in the treatment of medullary thyroid carcinoma. J Endocrinol Invest 2002; 25: 773-778.
176. Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M, Santoro M: Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004; 23: 6056-6063.
177. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M: BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006; 98: 326-334.